What is LOPJLB’s current signal on KOD?

LOPJLB’s latest quantitative signal on Kodiak Sciences Inc. (KOD) is BUY in a BULL regime. Signals are updated daily.

What market regime is KOD in?

Kodiak Sciences Inc. (KOD) is currently classified in the BULL HMM market regime on LOPJLB.

What does Kodiak Sciences Inc. (KOD) do?

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, …

Kodiak Sciences Inc. (KOD)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$91.63-7.69%Close

BUYBULL · day 12

Company news

schaeffersresearch.com · 2d ago

11 Stocks Most Likely to See a Short Squeeze Rally

prnewswire.com · 8d ago

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

marketbeat.com · 12d ago

Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study

defenseworld.net · 14d ago

Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Acquires 33,726 Shares of Company Stock

247wallst.com · 15d ago

A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?

zacks.com · 15d ago

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

defenseworld.net · 16d ago

Kodiak Sciences Inc. (NASDAQ: KOD) Advances Zenkuda Toward Filing

fool.com · 16d ago

Why Kodiak Sciences Skyrocketed Today

seekingalpha.com · 16d ago

Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript

proactiveinvestors.com · 16d ago

Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

gurufocus.com · 16d ago

Kodiak Sciences (KOD) Soars on Positive Phase 3 DAYBREAK Study Results

benzinga.com · 16d ago

Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine

defenseworld.net · 16d ago

Kodiak Sciences (NASDAQ:KOD) Hits New 52-Week High – Still a Buy?

investors.com · 16d ago

Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus

barrons.com · 17d ago

Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial

prnewswire.com · 19d ago

Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

zacks.com · 22d ago

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

defenseworld.net · 24d ago

Kodiak Sciences Inc. (NASDAQ:KOD) Receives $48.14 Consensus Target Price from Analysts

marketbeat.com · 31d ago

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

defenseworld.net · 49d ago

Algert Global LLC Purchases 38,546 Shares of Kodiak Sciences Inc. $KOD

Market news & ticker search · RSS for KOD

FAQ

What is LOPJLB’s current signal on KOD?: LOPJLB’s latest quantitative signal on Kodiak Sciences Inc. (KOD) is BUY in a BULL regime. Signals are updated daily.
What market regime is KOD in?: Kodiak Sciences Inc. (KOD) is currently classified in the BULL HMM market regime on LOPJLB.
What does Kodiak Sciences Inc. (KOD) do?: Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, …

Kodiak Sciences Inc. (KOD)

Key stats

Industry peers

Prediction markets

Company news

FAQ